Trimethoprim-Sulfamethoxazole or Levofloxacin? A Retrospective Cohort Study of Targeted Therapy for Stenotrophomonas Maltophilia Blood Stream and Lower Respiratory Tract Infections
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,621
- 试验地点
- 1
- 主要终点
- Death or hospice discharge
研究概览
简要总结
This study seeks to compare mortality outcomes of levofloxacin and trimethoprim-sulfamethoxazole treated patients who have Stenotrophomonas maltophilia blood stream or lower respiratory tract infections by retrospectively analyzing a propensity-matched cohort from a large dataset of electronic health record data.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age and older
- •Stenotrophomonas maltophilia culture positive from blood or the following specified respiratory tract sites: sputum, tracheal aspirate, bronchoalveolar lavage and protected bronchial brush washings
- •Received either levofloxacin or TMP/SMX targeted therapy
- •Those patients that received empiric therapy with a consistent medication (for example, levofloxacin empirically in the levofloxacin targeted therapy cohort) were included
排除标准
- •Received antimicrobial other than TMP/SMX and levofloxacin, with known activity against Stenotrophomonas maltophilia (the list of antimicrobials that fit this exclusion criteria is: erythromycin, moxifloxacin, ciprofloxacin, minocycline, tigecycline, doxycycline, eravacycline, ceftazidime, cefepime, ticarcillin-clavulanate, cefiderocol, colistin, and chloramphenicol)
- •Received inconsistent empiric therapy (for example, levofloxacin empirically in the TMP/SMX targeted therapy cohort) will be excluded from analysis
- •Cystic fibrosis code present
- •Organism resistant to therapy received
研究组 & 干预措施
Levofloxacin targeted therapy
Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received Levofloxacin from day of culture positivity (day 0) through day +7.
干预措施: Levofloxacin (Drug)
TMP/SMX targeted therapy
Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received TMP/SMX from day of culture positivity (day 0) through day +7.
干预措施: trimethoprim-sulfamethoxazole (Drug)
结局指标
主要结局
Death or hospice discharge
时间窗: In-hospital
Patient died or discharged to hospice
次要结局
- Hospital length of stay(Single encounter)
研究者
Sameer Kadri, M.D.
Staff Clinician, Critical Care Medicine Department
National Institutes of Health Clinical Center (CC)